An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A New 80 Mg (2x40 mg) Pediatric Appropriate Formulation To A 80 Mg Commercial Atorvastatin Calcium Tablet Formulation In Healthy Subjects.

Trial Profile

An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A New 80 Mg (2x40 mg) Pediatric Appropriate Formulation To A 80 Mg Commercial Atorvastatin Calcium Tablet Formulation In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Mar 2009

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Lipid metabolism disorders
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 25 Mar 2009 Actual patient number (76) added as reported by ClinicalTrials.gov.
    • 25 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 25 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top